Subscribe to RSS
DOI: 10.1055/s-0044-1785443
A Study of Safety and Effectiveness of Evicel Fibrin Sealant as an Adjunctive Hemostat in Pediatric Surgery
Abstract
Introduction Data on the use of fibrin sealants to control intraoperative bleeding in children are scarce. Evicel Fibrin Sealant (Ethicon Inc., Raritan, New Jersey, United States) was found safe and effective in clinical trials of adults undergoing various surgery types. We evaluated the safety and efficacy of Evicel versus Surgicel Absorbable Hemostat (Ethicon Inc.) as adjunctive topical hemostats for mild/moderate raw-surface bleeding in pediatric surgery.
Methods A phase III randomized clinical trial was designed as required by the European Medicines Agency's Evicel Pediatric Investigation Plan: 40 pediatric subjects undergoing abdominal, retroperitoneal, pelvic, or thoracic surgery were randomized to Evicel or Surgicel, to treat intraoperative mild-to-moderate bleeding. Descriptive analyses included time-to-hemostasis and rates of treatment success (4, 7, 10 minutes), intraoperative treatment failure, rebleeding, and thromboembolic events.
Results Forty of 130 screened subjects aged 0.9 to 17 years were randomized 1:1 to Evicel or Surgicel. Surgeries were predominantly open abdominal procedures. The median bleeding area was 4.0 cm2 for Evicel and 1.0 cm2 for Surgicel. The median time-to-hemostasis was 4.0 minutes for both groups. The 4-, 7-, and 10-minute treatment success rates were 80.0% versus 65.0%, 100.0% versus 80.0%, and 95.0% versus 90.0%, whereas treatment failure rates were 5.0% versus 25.0%, for Evicel and Surgicel, respectively. No deaths or thrombotic events occurred. Re-bleeding occurred in 5.0% of Evicel and 10.0% of Surgicel subjects.
Conclusions In accordance with adult clinical trials, this randomized study supports the safety and efficacy of Evicel for controlling mild-to-moderate surgical bleeding in a broad range of pediatric surgical procedures.
Publication History
Received: 11 October 2023
Accepted: 04 March 2024
Article published online:
29 March 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Corral M, Ferko N, Hollmann S, Broder MS, Chang E. Health and economic outcomes associated with uncontrolled surgical bleeding: a retrospective analysis of the Premier Perspectives Database. Clinicoecon Outcomes Res 2015; 7: 409-421
- 2 Al-Attar N, Johnston S, Jamous N. et al. Impact of bleeding complications on length of stay and critical care utilization in cardiac surgery patients in England. J Cardiothorac Surg 2019; 14 (01) 64
- 3 Ye X, Lafuma A, Torreton E, Arnaud A. Incidence and costs of bleeding-related complications in French hospitals following surgery for various diagnoses. BMC Health Serv Res 2013; 13: 186
- 4 Tompeck AJ, Gajdhar AUR, Dowling M. et al. A comprehensive review of topical hemostatic agents: the good, the bad, and the novel. J Trauma Acute Care Surg 2020; 88 (01) e1-e21
- 5 Chiara O, Cimbanassi S, Bellanova G. et al. A systematic review on the use of topical hemostats in trauma and emergency surgery. BMC Surg 2018; 18 (01) 68
- 6 Wright JD, Ananth CV, Lewin SN. et al. Patterns of use of hemostatic agents in patients undergoing major surgery. J Surg Res 2014; 186 (01) 458-466
- 7 Corral M, Ferko N, Hogan A. et al. A hospital cost analysis of a fibrin sealant patch in soft tissue and hepatic surgical bleeding. Clinicoecon Outcomes Res 2016; 8: 507-519
- 8 Ferko N, Danker W. Hemostat utilization training program achieves cost savings and utilization efficiency. Healthcare Purchasing News. 2017; 41 (11) 34-35
- 9 Zhong Y, Hu H, Min N, Wei Y, Li X, Li X. Application and outlook of topical hemostatic materials: a narrative review. Ann Transl Med 2021; 9 (07) 577
- 10 Fischer CP, Wood CG, Shen J. et al. A randomized trial of aprotinin-free fibrin sealant versus absorbable hemostat. Clin Appl Thromb Hemost 2011; 17 (06) 572-577
- 11 Schwartz M, Madariaga J, Hirose R. et al. Comparison of a new fibrin sealant with standard topical hemostatic agents. Arch Surg 2004; 139 (11) 1148-1154
- 12 Chalmers RT, Darling Iii RC, Wingard JT. et al. Randomized clinical trial of tranexamic acid-free fibrin sealant during vascular surgical procedures. Br J Surg 2010; 97 (12) 1784-1789
- 13 Gazzeri R, Fiore C, Galarza M. Role of EVICEL fibrin sealant to assist hemostasis in cranial and spinal epidural space: a neurosurgical clinical study. Surg Technol Int 2015; 26: 364-369
- 14 Fibrin Sealant EVICEL. . (Human). Highlights of prescribing information. 2013 . Article No. 80FZ00M3-4. Accessed June 20, 2023 at: https://www.fda.gov/media/81499/download
- 15 EVICEL. Summary of product characteristics. EMA number EMEA/H/C/000898/IA/0085. 2021 . Accessed June 20, 2023 at: https://www.ema.europa.eu/en/documents/product-information/evicel-epar-product-information_en.pdf
- 16 Armstrong SA, Nguyen HTN, Rebsamen SL, Iskandar B, Stadler III JA. Epidural fibrin sealant injection for the management of cerebrospinal fluid leak following dural puncture in children. Cureus 2020; 12 (02) e6940
- 17 Roberts JM, Peterson VE, Heran MKS. Percutaneous CT-guided epidural fibrin sealant injection for refractory pediatric post-dural puncture headache. Pediatr Radiol 2020; 50 (08) 1156-1158
- 18 Sojo ET, Grosman MD, Monteverde ML, Bailez MM, Delgado N. Fibrin glue is useful in preventing early dialysate leakage in children on chronic peritoneal dialysis. Perit Dial Int 2004; 24 (02) 186-190
- 19 Rusthoven E, van de Kar NA, Monnens LA, Schröder CH. Fibrin glue used successfully in peritoneal dialysis catheter leakage in children. Perit Dial Int 2004; 24 (03) 287-289
- 20 Hisamatsu C, Maeda K, Aida Y. et al. A novel technique of catheter placement with fibrin glue to prevent pericatheter leakage and to enable no break-in period in peritoneal dialysis. J Pediatr Urol 2015; 11 (05) 299-300
- 21 Liao FT, Chang CJ. Initial experience with fibrin glue treatment of anal fistulae in children. Am Surg 2018; 84 (06) 1105-1109
- 22 Chu JK, Miller BA, Bazylewicz MP, Holbrook JF, Chern JJ. Repair of a traumatic subarachnoid-pleural fistula with the percutaneous injection of fibrin glue in a 2-year-old. J Neurosurg Pediatr 2016; 17 (01) 13-18
- 23 Hardy E, Herrod P, Sian T. et al. Fibrin glue obliteration is safe, effective and minimally invasive as first line treatment for pilonidal sinus disease in children. J Pediatr Surg 2019; 54 (08) 1668-1670
- 24 Kwa KA, Pijpe A, Korte D, Snoeks A, Breederveld RS, Meij-de Vries A. Using fibrin sealant for skin graft fixation to avoid sedation in children with burns: a prospective study. J Wound Care 2020; 29 (11) 642-648
- 25 Spotnitz WD. Fibrin sealant: the only approved hemostat, sealant, and adhesive-a laboratory and clinical perspective. ISRN Surg 2014; 2014: 203943
- 26 Weatherall JM, Price AE. Fibrin glue as interposition graft for tarsal coalition. Am J Orthop 2013; 42 (01) 26-29
- 27 Mirza D, Millar AJ, Sharif K, Vilca-Melendez H, Rela M, Heaton N. The use of TachoSil in children undergoing liver resection with or without segmental liver transplantation. Eur J Pediatr Surg 2011; 21 (02) 111-115
- 28 Kim YW, Kang MJ, Lee HJ, Woo CK, Mun MJ, Cho KS. The efficacy of TachoComb on reducing postoperative complications after tonsillectomy in children. Int J Pediatr Otorhinolaryngol 2015; 79 (08) 1337-1340
- 29 Segal N, Puterman M, Rotem E. et al. A prospective randomized double-blind trial of fibrin glue for reducing pain and bleeding after tonsillectomy. Int J Pediatr Otorhinolaryngol 2008; 72 (04) 469-473
- 30 Cheikh A, Ajaja MR, Rhazali H. et al. Contribution of fibrin glue in the surgery of cyanogenic and non-cyanogenic congenital cardiopathies: retrospective cohort study. BMC Cardiovasc Disord 2019; 19 (01) 117
- 31 Guidance on clinical investigation of plasma-derived fibrin sealants. (CPMP/BPWG/1089/00, July 29, 2004 ). EMEA Committee for medicinal products for human use (CHMP). Accessed June 20, 2023 at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-plasma-derived-fibrin-sealant/haemostatic-products-cpmp/bpwg/1089/00_en.pdf
- 32 MacDonald MH, Zhang G, Tasse L, Wang D, De Leon H, Kocharian R. Hemostatic efficacy of two topical adjunctive hemostats in a porcine spleen biopsy punch model of moderate bleeding. J Mater Sci Mater Med 2021; 32 (10) 127
- 33 Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Guideline for prevention of surgical site infection, 1999. Am J Infect Control 1999; 27 (02) 97-132 , quiz 133–134, discussion 96
- 34 SURGICEL ® ORIGINAL, SURGICEL ® NU-KNIT™ and SURGICEL ® FIBRILLAR™ Absorbable hemostats instructions for use. Accessed June 20, 2023 at: https://www.jnjmedtech.com/en-US/platform/adjunctive-hemostats
- 35 Attard C, van der Straaten T, Karlaftis V, Monagle P, Ignjatovic V. Developmental hemostasis: age-specific differences in the levels of hemostatic proteins. J Thromb Haemost 2013; 11 (10) 1850-1854
- 36 Andrew M, Paes B, Milner R. et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70 (01) 165-172
- 37 Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood 1992; 80 (08) 1998-2005
- 38 Appel IM, Grimminck B, Geerts J, Stigter R, Cnossen MH, Beishuizen A. Age dependency of coagulation parameters during childhood and puberty. J Thromb Haemost 2012; 10 (11) 2254-2263